This article examines The Epp Report. Discuses the proposed movement from the individual model. Illustrates the value of the report in terms of health promotion and health strategies.
This article discusses how the marketing of controversial drugs in developing countries demonstrates the power and priorities of the pharmaceutical industry. Example highlighted: Estrogen-Progesterone combination drugs.
This article shares the story of Diethylstilbestrol, commonly known as DES, a drug introduced in the forties to prevent miscarriage. Identifies harmful effects on daughters and sons of women who took this drug.
This article illustrates, through a historical overview, how our concerns as patients are inseparably linked with the structure of hospital work and the well being of workers. Proposes a united and creative front in the battle to end the dehumanization of patients and workers.
This article discusses depo provera. Highlights the controversy of discriminatory and unsafe research methods, discusses the drug industry, potential health effects on women, racist practices.
This article discusses the serious problem of over-the-counter (OTC) analgesic abuse; questions why this is predominantly a women’s problem, causes kidney damage, critically explores the role of advertising and big business in women’s increased consumption of OTC’s.
Drug assessment specialist Dr. Barbara Mintzes looks at the ways women’s sexual difficulties are being repackaged as symptoms of a disorder called “female sexual dysfunction” in order to feed a marketing machine that promises to “cure” it. Dr. Mintzes and Ray Moynihan co-authored the book, Sex, Lies, and Pharmaceuticals.
Reviews and analyzes disease awareness campaigns sponsored by pharmaceutical companies that use self-diagnostic tools. Uses the example of premenstrual dysphoric disorder (PMDD) to discuss how the marketing of self-diagnosis can change the patient into a consumer to achieve the aims of drug companies. (Abstract only)
PharmaWatch’s blog seeks to shed light on some of the most significant policy, research, legislative and program issues related to the safety and efficacy of prescription drugs, vaccines and medical devices in Canada. They believe that the Canadian public, patients, physicians, policy analysts, researchers, academics, authors, politicians and the media have a right to know how our drug approval and monitoring system works, how it compares to other international jurisdictions, the factors influencing decision making and whether Health Canada is protecting our health and safety.
